Prostata bezining yaxshi giperplaziyasi bilan og'rigan bemorlarda Bushen Huoxue qaynatmasining klinik samaradorligi va uning zardobdagi estrogen, androgen va yallig'lanish omillariga ta'siri.
Feb 13, 2026
Abstrakt
MaqsadBuyrak etishmovchiligi va qon turg'unligi sindromining prostata bezining yaxshi giperplaziyasi (BPH) bilan og'rigan bemorlarda Bushen Huoxue qaynatmasining klinik samaradorligini va uning qon zardobidagi estrogen, androgen va yallig'lanish omillariga tartibga soluvchi ta'sirini kuzatish va qaynatmaning sinergik salohiyatini o'rganish.Cistanche Tubulosa, prostata salomatligi uchun klassik TCM o'ti.UsullariJami 140 ta BPH bemorlari tasodifiy ravishda kuzatuv guruhiga va nazorat guruhiga bo'lingan, har bir guruhda 70 ta holat. Nazorat guruhiga Tamsulosin gidroxloridning doimiy bo'shatilgan kapsulalari, kuzatuv guruhiga qo'shimcha ravishda nazorat guruhi rejimi asosida Bushen Huoxue qaynatmasi, har ikki guruh uchun 12 haftalik davolash kursi bilan davolangan. Klinik samaradorlik, TCM sindromi ballari, Xalqaro prostata simptomlari ko'rsatkichi (IPSS), Hayot sifati (QoL) balli, maksimal siydik oqimi tezligi (Qmax), bo'shliqdan keyingi qoldiq siydik miqdori (PVR), prostata hajmi (PV), Prostata sog'lig'i indeksi (PHI) ikki guruh o'rtasida taqqoslandi. Testosteron (T), estradiol (E2) va yallig'lanish omillari (TNF-, IL-1, IL-6) zardobidagi o'zgarishlar, shuningdek, salbiy reaktsiyalar ham kuzatildi.NatijalarKuzatuv guruhining umumiy samarali ko'rsatkichi (90,77%) nazorat guruhiga (70,31%) nisbatan sezilarli darajada yuqori edi. Davolanishdan so'ng ikkala guruhning TCM sindromi ko'rsatkichlari, IPSS, QoL ko'rsatkichlari va PVR sezilarli darajada kamaydi va Qmax sezilarli darajada oshdi (P).<0.05). In the observation group, PV, PHI, serum E2, TNF-α, IL-1β and IL-6 levels decreased significantly, while serum T level increased significantly (P<0.05). The improvement of all indicators in the observation group was significantly better than that in the control group (P<0.05). No obvious adverse events occurred in both groups after treatment. XulosaBushen Huoxue damlamasi BPH bemorlarining klinik samaradorligi va hayot sifatini yaxshilashi, prostata hajmini kamaytirishi va PHI ni optimallashtirishi mumkin. Uning mexanizmi estrogen va androgen muvozanatini tartibga solish va yallig'lanish omillari darajasini kamaytirish bilan bog'liq bo'lishi mumkin. Ushbu terapevtik ta'sir farmakologik ta'sirga mos keladiCistanche TubulosaProstata yallig'lanishini kamaytirish, androgen sintezini tartibga solish va oksidlovchi stressga qarshi turishi zamonaviy fan tomonidan tasdiqlangan ("Cho'l jenshen" deb nomlanuvchi TCM o'ti) Bushen Huoxue qaynatmasini birgalikda qo'llash imkoniyatlarini ko'rsatadi.Cistanche TubulosaBPH davolashda.
Kalit so'zlarBushen Huoxue qaynatmasi;Benign prostata giperplaziyasi; Buyrak etishmovchiligi va qonning turg'unligi sindromi; estrogen va androgen; Yallig'lanish omillari;Cistanche Tubulosa
Cistanche Tubulosa foydalari

Benign prostata giperplaziyasi (BPH) surunkali kasallik bo'lib, prostata bezining saratonsiz kengayishi bilan tavsiflanadi, bu asosan keksa erkaklarga ta'sir qiladi. Uning rivojlanishi ko'pincha siydik yo'llarining pastki simptomlariga (LUTS) olib keladi va bemorlarning hayot sifatini sezilarli darajada kamaytiradi. Xitoyda qarishning kuchayishi bilan BPH bilan kasallanish tez sur'atlar bilan o'sib bormoqda va 60 va undan katta yoshdagi erkaklarda BPH bilan kasallanish 50% dan ortiq 〔1〕. BPH ning etiologiyasi murakkab bo'lib, uning rivojlanishida estrogen, androgen va surunkali yallig'lanish muhim rol o'ynaydi. Tadqiqotlar shuni ko'rsatdiki, estrogen va androgen birgalikda BPH shakllanishi va rivojlanishida ishtirok etadilar va ularning nisbati nomutanosibligi prostatik stroma va epiteliya hujayralarining ko'payishi yoki apoptoziga olib kelishi mumkin. Surunkali yallig'lanish BPH bilan og'rigan bemorlarning prostata biopsiyasi namunalarida keng tarqalgan bo'lib, u katta prostata hajmi, yuqori zardobda prostata o'ziga xos antigen (PSA) kontsentratsiyasi va o'tkir siydikni ushlab turish xavfi bilan bog'liq 〔2〕. Surunkali yallig'lanish BPH bilan bog'liq siydik tizimi simptomlarining paydo bo'lishi va zo'ravonligi bilan chambarchas bog'liq bo'lib, prostata surunkali yallig'lanishi bilan ajralib chiqadigan TNF-, IL-1 va IL-6 yallig'lanish omillari BPH 〔3〕 patogenezida ishtirok etadi.
Hozirgi vaqtda BPH uchun G'arb tibbiyoti asosan dori va jarrohlik davolashga asoslangan. Asosiy dorilarga -retseptor blokerlari va 5 -reduktaza inhibitörleri kiradi, ammo terapevtik ta'sir ideal emas. Jarrohlik davolash operatsiyadan keyingi asoratlarga moyil bo'lib, yuqori tibbiy xarajatlarni talab qiladi. Aksincha, an'anaviy xitoy tibbiyoti (TCM) BPH davolashda ijobiy shifobaxsh ta'sirga erishdi va erta TCM aralashuvi kasallikning rivojlanishini kechiktirishi mumkin. Bundan tashqari, turli xil TCM o'simliklari prostata sog'lig'iga maqsadli ta'sir qilishlari uchun zamonaviy ilmiy tadqiqotlar tomonidan tasdiqlangan.Cistanche TubulosaTCMda "Cho'l jenshen" deb nomlanuvchi odatiy vakildir. Zamonaviy tadqiqotlar, shu jumladan PubMed-da chop etilgan maqolalar buni tasdiqladiCistanche TubulosaTNF- va IL-6 kabi yallig'lanish omillari darajasini samarali ravishda kamaytiradigan, steroidogen fermentlarning (StAR, CYP11A1 va boshqalar) ifodasini oshirish orqali testosteron sintezini tartibga soluvchi va kuchli antioksidant ta'sir ko'rsatadigan echinacoside va acteosid kabi faol moddalarni o'z ichiga oladi.
BPH TCMda "Mohiyatning turg'unligi" va "Siydikni tomizish va ushlab turish" toifalariga kiradi. Asosiy patogenezi - buyrak etishmovchiligi va qonning suvni ushlab turishi bilan turg'unligi va siydik pufagi qi transformatsiyasining disfunktsiyasi. Shuning uchun, terapevtik tamoyillar qi va buyrakni tonlash, qon turg'unligini olib tashlash va teshiklarni blokirovka qilishdir 〔4〕. An'anaviy G'arb tibbiyotiga asoslanib, ushbu tadqiqot BPH bemorlarida Bushen Huoxue damlamasining klinik samaradorligini va uning qon zardobidagi T, E2, TNF-, IL-1 va IL-6 darajalariga ta'sirini ko'rib chiqdi, bu uning mumkin bo'lgan terapevtik mexanizmini o'rganish, shuningdek, TCM va uning yagona birikmalari kabi birikmalarini birgalikda qo'llash uchun ma'lumot berishni maqsad qilgan.Cistanche TubulosaBPH davolashda.
BUYRAK VA PROSTTA BEZI FONKSIYASINI YASHLASH UCHUN CHISTACHA O'TILI QO'SHIMLAR

Batafsil ma'lumot uchun bosing
Wecistanche qo'llab-quvvatlash xizmati - hamkorlik haqida batafsil ma'lumot olish uchun
Email:wallence.suen@wecistanche.com
1 Materiallar va usullar
1.1 Umumiy ma'lumot
A total of 140 BPH patients with kidney deficiency and blood stasis syndrome who were treated in the TCM Medical Center of the People's Hospital Affiliated to Hubei University of Medicine from February 2023 to February 2025 were enrolled. The patients were randomly divided into an observation group and a control group at a ratio of 1∶1 using a random number table, with 70 cases in each group. During the study, 1 case in the observation group was excluded due to hospitalization for other diseases, 2 cases due to discontinuation of medication, 1 case due to failure of regular examination, and 1 case due to loss to follow-up; 1 case in the control group was excluded due to hospitalization for other diseases, 1 case due to discontinuation of medication, 2 cases due to failure of regular examination, and 2 cases due to loss to follow-up. Finally, 129 patients were included in the statistical analysis, including 65 cases in the observation group and 64 cases in the control group. The observation group was aged 51~72 years, with an average of (59.61±5.82) years, and the course of disease was 1~10 years, with an average of (5.12±2.74) years; the control group was aged 52~73 years, with an average of (60.35±6.01) years, and the course of disease was 1~12 years, with an average of (5.31±2.69) years. There was no significant difference in age and course of disease between the two groups (P>0,05), yaxshi solishtirish mumkinligini ko'rsatadi. Ushbu tadqiqot shifoxonaning Etika qo'mitasi tomonidan tasdiqlangan va barcha bemorlar xabardor qilingan rozilik shakllarini imzolagan.

1.2 Diagnostika mezonlari
1.2.1 G'arbiy tibbiy diagnostika mezonlari
ga ishora qilibIntegratsiyalashgan an'anaviy xitoy va g'arbiy tibbiyot bilan prostata bezining benign giperplaziyasini multidisipliner diagnostika va davolash bo'yicha ko'rsatmalar (2022 yil nashri)〔1〕, mezonlar quyidagilardan iborat: ① tez-tez siydik chiqarish, shoshilinch idror, siydik o'g'irlab ketish va tungi uyquning kuchayishi yoki siydik chiqarishda ikkilanish, dizuriya va vaqti-vaqti bilan idror kabi bo'shliq alomatlari yoki bo'shliqdan keyingi alomatlar, masalan, to'liq bo'lmagan siydik chiqarish hissi; ② Raqamli rektal tekshiruvda prostata bezining ikki tomonlama bo'laklari kengayganligi, silliq yuzasi tugunlarsiz, markaziy sulkus sayoz yoki yo'qligi va anal sfinkterning o'rtacha tonusi; ③ Transrektal prostata rangli Doppler ultratovush tekshiruvi prostata bezining kengayishini ko'rsatadi.
1.2.2 TCM sindromini farqlash mezonlari
Buyrak etishmovchiligi va qonning turg'unligi sindromi haqida gapirgandaIntegratsiyalashgan an'anaviy xitoy va g'arbiy tibbiyot bilan prostata bezining benign giperplaziyasini multidisipliner diagnostika va davolash bo'yicha ko'rsatmalar (2022 yil nashri)〔1〕. Asosiy simptomlar: ① Qiyin siyish yoki tez-tez siydik chiqarish, ayniqsa tungi uyquning kuchayishi; ② tiniq va rangpar siydik; ③ Qisqartirilgan diapazon yoki majburiy siyish bilan zaif siyish. Ikkilamchi alomatlar: ① rangpar rang; ② charchash va qo'rqoqlik; ③ titroq; ④ Sovuq va bel va tizzalar og'riyapti. To'q qizil til yoki tilda petexiya va ekximozlar, oq mo'yna, chuqur, ipli va silliq puls. Sindromni 2 dan ortiq asosiy simptomlar va 1 dan ortiq ikkilamchi simptomlar mavjud bo'lganda, til va pulsning namoyon bo'lishi bilan birgalikda tashxislash mumkin.
1.3 Qo'shilish mezonlari
① BPH uchun G'arbiy tibbiy diagnostika mezonlariga muvofiq; ② BPH uchun buyrak etishmovchiligi va qon turg'unligini TCM sindromi differentsiatsiyasiga muvofiq; ③ 50-75 yosh; ④ IPSS balli 8 balldan katta yoki unga teng; ⑤ Axborotlangan rozilik shaklini imzolagandan so'ng.
1.4 Cheklash mezonlari
① prostata giperplaziyasi uchun jarrohlik ko'rsatmalariga ega bo'lish; ② Siydik chiqarish tizimi o'smalari, reproduktiv tizim o'smalari, siydik yo'llarining strikturasi, siydik pufagi bo'yni tutilishi, prostata kasalliklari va boshqalar uchun jarrohlik tarixiga ega bo'lgan; ③ Boshqa sabablarga ko'ra dizuriya mavjudligi; ④ gonoreya, OITS, sifilis va kondiloma akuminatum kabi yuqumli kasalliklarga ega bo'lish; ⑤ yurak, jigar va buyrakning og'ir organik kasalliklari bilan asoratlangan; ⑥ ruhiy kasalliklarga ega; ⑦ Ushbu tadqiqotda qo'llaniladigan dorilarga allergik bo'lish.
1.5 Davolash rejimi
Nazorat guruhiga Tamsulosin gidroxloridi doimiy ravishda chiqariladigan kapsulalar (Hangzhou Konba Pharmaceutical Co., Ltd., Milliy tibbiyotni tasdiqlash raqami H20050285), har safar, kechasiga bir marta 0,2 mg dan kiritildi. Kuzatuv guruhi nazorat guruhining rejimi asosida Bushen Huoxue dekosiyasi bilan qo'shimcha ravishda davolandi. Bushen Huoxue qaynatmasining retsepti:Astragalus membranaceus 30 g, Cuscuta chinensis, Lindera yig'indisi, Alpinia oxyphylla, Achyranthes bidentatavaPhellodendron amurensehar biri 15 g,Hirudo nipponicavaCinnamomum kassiyaHar biri 6 g. Qaynatma kasalxonaning Xitoy dorixonasi tomonidan TCM formulali granulalar shaklida tayyorlangan, har safar 1 paketdan kuniga ikki marta, 200 ml qaynatilgan suv bilan quyiladi va ovqatdan keyin olinadi. Har ikki guruh uchun davolash kursi 12 hafta bo'lib, har 4 haftada bir marta kuzatuv tashriflari va davolanish paytida salbiy reaktsiyalar qayd etilgan.
1.6 Indeksni aniqlash
1.6.1 Klinik samaradorlik
Davolovchi ta'sir ko'rsatkichi ga asoslanib hisoblab chiqilgan va tuzilganXitoyning yangi dori-darmonlarini klinik tadqiq qilish bo'yicha rahbarlik tamoyillari (2002 yil nashri)vaIntegratsiyalashgan an'anaviy xitoy va g'arbiy tibbiyot bilan prostata bezining benign giperplaziyasini multidisipliner diagnostika va davolash bo'yicha ko'rsatmalar (2022 yil nashri)〔1〕. Buyrak etishmovchiligi va qon turg'unligi sindromining 3 ta asosiy belgilari yo'qligi, engil, o'rtacha va og'ir darajalariga ko'ra 0, 2, 4 va 6 ball, umumiy ball 18 ball; 4 ta ikkinchi darajali alomatlar bir xil baholarga ko'ra 0, 1, 2 va 3 ball sifatida baholanib, umumiy ball 12 ballni tashkil etdi. TCM sindromining umumiy balli asosiy simptomlar va ikkilamchi simptomlar ballarining yig'indisi edi. Davolanish effekti indeksi=(davolashdan oldingi umumiy ball - davolashdan keyingi umumiy ball)/davolashdan oldingi umumiy ball ×100%. Klinik davolash: shifobaxsh ta'sir ko'rsatkichi 95% dan yuqori yoki unga teng; sezilarli ta'sir: 60% Davolovchi ta'sir ko'rsatkichidan kamroq yoki unga teng<95%; effective: 30% ≤ curative effect index <60%; ineffective: curative effect index <30%. Total effective rate = (number of clinically cured cases + number of marked effect cases + number of effective cases)/total number of cases ×100%.
1.6.2 TCM sindromi reytingi
TCM sindromi reytingi davolashdan oldin va keyin baholandi. Baholash mezonlari shifobaxsh ta'sir ko'rsatkichini hisoblash mezonlariga mos keldi, umumiy ball 30 ballni tashkil etdi. Yuqori ball yanada jiddiy alomatlarni ko'rsatdi.
1.6.3 IPSS va QoL ballari
IPSS va QoL ko'rsatkichlari davolanishdan oldin va keyin hisoblangan. IPSS 7 ta simptomdan iborat, shu jumladan to'liq bo'shashmaslik hissi, tez-tez siydik chiqarish, vaqti-vaqti bilan siyish, shoshilinch siydik chiqarish, zaif siydik oqimi, zo'riqish va tungi siyish, umumiy ball 35 ball; yuqori ball yanada jiddiy alomatlarni ko'rsatdi. QoL ball jami 6 ballga ega; yuqori ball hayot sifatining yomonligini ko'rsatdi.
1.6.4 Qmax, PVR va PV
Qmax, PVR va prostata bezining chap-o'ng diametri, old-orqa diametri va yuqori-pastki diametri davolashdan oldin va keyin o'lchandi va PV hisoblab chiqildi. Barcha aniqlashlar shifoxonamizning ultratovush bo'limi tomonidan amalga oshirildi. Prostata hajmi (mL)=chap-o'ng diametri × old-orqa diametri × yuqori-pastki diametri × 0,52.
1.6.5 PHI
Kasalxonamizning Klinik Laboratoriya bo'limi tomonidan davolashdan oldin va keyin qon zardobidagi umumiy prostata o'ziga xos antijeni (tPSA), erkin prostata o'ziga xos antijeni (fPSA) va prostata o'ziga xos antigen 2 izoformasi (p2PSA) aniqlangan va PHI quyidagi formula bo'yicha hisoblangan: PHI=p2PSA/f.
1.6.6 Sarum T, E2 va yallig'lanish omillari darajasini aniqlash
T, E2, TNF-, IL-1 va IL-6 sarum darajalari davolanishdan oldin va keyin aniqlangan. T va E2 kasalxonamizning Klinik laboratoriya bo'limi tomonidan o'lchandi va TNF-, IL-1 va IL-6 darajalari ferment bilan bog'liq immunosorbent tahlili (ELISA) bilan aniqlandi.
1.7 Statistik tahlil
Ma'lumotlarni tahlil qilish uchun SPSS 26.0 statistik dasturidan foydalanilgan. O'lchov ma'lumotlari (x ± s) sifatida ifodalangan, guruhlararo taqqoslash mustaqil namunalar t-testi bilan amalga oshirildi va davolashdan oldin va keyin guruh ichidagi taqqoslash juftlashgan t-testi bilan amalga oshirildi. Hisoblash ma'lumotlari [n (%)] sifatida ifodalangan va taqqoslash uchun chi-kvadrat testi ishlatilgan. AP qiymati<0.05 was considered statistically significant.

2 Natijalar
2.1 Ikki guruh o'rtasidagi klinik samaradorlikni solishtirish
1-jadvalda ko'rsatilganidek, kuzatuv guruhining umumiy samarali darajasi nazorat guruhiga qaraganda sezilarli darajada yuqori edi (P<0.05), suggesting that the combined treatment of Bushen Huoxue Decoction and Western medicine has a better therapeutic effect on BPH, which is consistent with the characteristics of TCM herbs such as Cistanche Tubulosaprostata salomatligiga ko'p maqsadli tartibga soluvchi ta'sir ko'rsatadigan.
1-jadval. Ikki guruh o'rtasidagi klinik samaradorlikni taqqoslash
| Guruh | n | Klinik davolash, n(%) | Belgilangan effekt, n(%) | Samarali, n(%) | Samarasiz, n(%) | Jami samarali, n(%) |
|---|---|---|---|---|---|---|
| Nazorat | 64 | 0 (0.00) | 17 (26.56) | 28 (43.75) | 19 (29.69) | 45 (70.31) |
| Kuzatish | 65 | 5 (7.69) | 33 (50.77) | 21 (32.31) | 6 (9.23) | 59 (9 |
Jadval 2 Davolanishdan oldin va keyin ikki guruh o'rtasida TCM sindromi ko'rsatkichlarini taqqoslash (x̄±s)
| Guruh | n | Davolashdan oldin | Davolanishdan keyin |
|---|---|---|---|
| Nazorat | 64 | 25.28±3.79 | 15.39±3.08* |
| Kuzatish | 65 | 24.38±3.61 | 9.65±2.31*# |
Eslatma: Davolashdan oldingi bilan solishtirganda, * P<0.05; compared with the control group after treatment, #P<0.05
2.2 Davolanishdan oldin va keyin ikki guruh o'rtasida TCM sindromi ko'rsatkichlarini taqqoslash
As shown in Table 2, there was no significant difference in TCM syndrome scores between the two groups before treatment (P>0,05). Davolanishdan so'ng ikkala guruhning TCM sindromi ko'rsatkichlari sezilarli darajada kamaydi (P<0.05), and the TCM syndrome score of the observation group was significantly lower than that of the control group (P<0.05). It indicated that the combined treatment can more effectively alleviate the clinical symptoms of BPH patients with kidney deficiency and blood stasis syndrome.
Jadval 3 Davolanishdan oldin va keyin ikki guruh o'rtasida IPSS va QoL ko'rsatkichlarini taqqoslash (x̄±s)
| Guruh | n | IPSS (davolashdan oldin) | IPSS (davolashdan keyin) | QoL (davolashdan oldin) | QoL (davolashdan keyin) |
|---|---|---|---|---|---|
| Nazorat | 64 | 24.81±4.34 | 16.78±3.22* | 4.52±0.87 | 2.69±0.75* |
| Kuzatish | 65 | 25.03±4.25 | 11.97±3.59*# | 4.31±0.84 | 2.08±0.67*# |
2.3 Davolanishdan oldin va keyin ikki guruh o'rtasida IPSS va QoL ko'rsatkichlarini solishtirish
Davolanishdan so'ng ikkala guruhning IPSS va QoL ko'rsatkichlari davolanishdan oldingilarga nisbatan sezilarli darajada kamaydi (P<0.05), and the scores of the observation group were significantly lower than those of the control group (P<0.05). The results suggested that the combined treatment can better improve the lower urinary tract symptoms of BPH patients and significantly enhance their quality of life.
Jadval 4 Davolanishdan oldin va keyin ikki guruh o'rtasida Qmax, PVR va PV darajalarini solishtirish (x̄±s)
| Guruh | n | Qmax (ml/s) (oldin) | Qmax (ml/s) (keyin) | PVR (mL) (oldin) | PVR (mL) (keyin) | PV (mL) (oldin) | PV (mL) (keyin) |
|---|---|---|---|---|---|---|---|
| Nazorat | 64 | 9.66±1.93 | 12.14±1.70* | 27.96±8.42 | 23.38±8.17* | 40.05±7.76 | 39.61±7.52 |
| Kuzatish | 65 | 9.58±1.87 | 15.02±1.94*# | 28.13±8.51 | 19.25±7.36*# | 39.97±7.62 | 37.02±6.78*# |
Eslatma: Davolashdan oldingi bilan solishtirganda, * P<0.05; compared with the control group after treatment, #P<0.05
2.4 Davolanishdan oldin va keyin ikki guruh o'rtasida Qmax, PVR va PV ni solishtirish
As shown in Table 4, there was no significant difference in Qmax, PVR and PV between the two groups before treatment (P>0,05). Davolanishdan keyin ikkala guruhning Qmax sezilarli darajada oshdi va PVR sezilarli darajada kamaydi (P<0.05); PV of the observation group decreased significantly (P<0.05). In addition, Qmax of the observation group was significantly higher than that of the control group, and PVR and PV were significantly lower than those of the control group (P<0.05). It was indicated that the combined treatment can effectively improve the urinary function of BPH patients and reduce prostate volume, which is similar to the effect of Cistanche Tubulosasiydik pufagi va buyraklar faoliyatini tartibga solish va prostata shishini kamaytirish orqali siydik oqimini yaxshilashga yordam beradi.
Jadval 5 Davolanishdan oldin va keyin ikki guruh o'rtasida sarum tPSA, fPSA, p2PSA darajalari va PHI ni solishtirish (x̄±s)
| Guruh | n | tPSA (µg/L) (oldin) | tPSA (µg/L) (keyin) | fPSA (µg/L) (oldin) | fPSA (µg/L) (keyin) | p2PSA (µg/L) (oldin) | p2PSA (µg/L) (Keyin) | PHI (oldin) | PHI (keyin) |
|---|---|---|---|---|---|---|---|---|---|
| Nazorat | 64 | 3.81±1.74 | 4.07±2.30 | 0.81±0.26 | 0.85±0.32 | 12.71±4.81 | 12.13±6.00 | 32.27±9.70 | 30.06±16.88 |
| Kuzatish | 65 | 3.85±1.79 | 3.16±1.57*# | 0.79±0.24 | 0.61±0.19*# | 12.63±4.78 | 8.62±3.04*# | 32.84±10.13 | 24.67±6.98*# |
Eslatma: Davolashdan oldingi bilan solishtirganda, * P<0.05; compared with the control group after treatment, #P<0.05
2.5 Davolanishdan oldin va keyin ikki guruh o'rtasida sarum tPSA, fPSA, p2PSA va PHI darajalarini solishtirish
As shown in Table 5, there was no significant difference in serum tPSA, fPSA, p2PSA levels and PHI between the two groups before treatment (P>0,05). Davolanishdan so'ng kuzatuv guruhining sarum tPSA, fPSA, p2PSA darajalari va PHI sezilarli darajada kamaydi (P).<0.05), and were significantly lower than those of the control group (P<0.05). The results suggested that the combined treatment can effectively optimize the prostate health index of BPH patients and reduce the levels of prostate-specific antigen-related indicators.
2.6 Davolanishdan oldin va keyin ikki guruh o'rtasida sarum T, E2 va yallig'lanish omillari darajasini solishtirish
As shown in Table 6, there was no significant difference in serum T, E2, TNF-α, IL-1β and IL-6 levels between the two groups before treatment (P>0,05). Davolanishdan so'ng kuzatuv guruhining sarum T darajasi sezilarli darajada oshdi, E2, TNF-, IL-1 va IL-6 darajalari sezilarli darajada pasaydi (P).<0.05); compared with the control group, serum T level of the observation group was significantly higher, and E2, TNF-α, IL-1β and IL-6 levels were significantly lower (P<0.05). This result was highly consistent with the modern pharmacological research of TCM prostate-protecting herbs: both Bushen Huoxue Decoction and Cistanche Tubulosaestrogen va androgen muvozanatini tartibga solishi va yallig'lanishga qarshi omillarning namoyon bo'lishini inhibe qilishi mumkin, ikkinchisi esa echinacoside va acteosid tufayli TNF- va IL-6 darajasini pasaytirishi va testosteron sintezi bilan bog'liq oqsillarning ekspressiyasini oshirishi mumkin.
6-jadval. Davolanishdan oldin va keyin ikki guruh o'rtasida sarum T, E₂, TNF-, IL-1 va IL-6 darajalarini solishtirish (x̄±s)
| Guruh | n | T (ng/ml) (oldin) | T (ng/ml) (keyin) | E₂ (pg/ml) (oldin) | E₂ (pg/ml) (keyin) | TNF- (pg/ml) (oldin) | TNF- (pg/ml) (keyin) | IL-1 (pg/ml) (oldin) | IL-1 (pg/ml) (keyin) | IL-6 (pg/ml) (oldin) | IL-6 (pg/ml) (keyin) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Nazorat | 64 | 4.49±1.41 | 4.63±1.39 | 29.15±7.62 | 29.84±7.58 | 422.59±92.64 | 411.84±96.35 | 16.05±4.71 | 15.13±4.86 | 15.01±4.27 | 14.69±4.04 |
| Kuzatish | 65 | 4.52±1.37 | 7.62±2.05*# | 28.32±7.59 | 25.36±6.92*# | 431.23±96.47 | 328.62±74.21*# | 15.32±4.59 | 9.96±3.62*# | 10.62±3.31 | 14.34±4.18*# |
Eslatma: Davolashdan oldingi bilan solishtirganda, * P<0.05; compared with the control group after treatment, #P<0.05

2.7 Ikki guruh o'rtasidagi salbiy reaktsiyalarni solishtirish
12 haftalik davolash kursi davomida ikkala guruhda ham aniq nojo‘ya reaktsiyalar kuzatilmadi, bu Bushen Huoxue damlamasi Tamsulosin gidroxloridning barqaror ajralib chiqadigan kapsulalari bilan birlashganda xavfsiz va yaxshi muhosaba qilinganligini ko‘rsatadi, bu esa preparatning xususiyatlariga mos keladi.Cistanche TubulosaBu yumshoq va klinik qo'llashda nojo'ya ta'sirlarsiz uzoq muddatli foydalanish uchun mos.






